An Open Label, Phase 1 Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Cenicriviroc (CVC)

Trial Profile

An Open Label, Phase 1 Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Cenicriviroc (CVC)

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2016

At a glance

  • Drugs Cenicriviroc (Primary)
  • Indications Graft-versus-host disease; Hepatic fibrosis; HIV-1 infections; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 13 May 2016 According to a Tobira Therapeutics media release, results from this trial were published in the journal Clinical Translational Science.
    • 13 May 2016 Results published in the Tobira Therapeutics media release.
    • 20 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top